Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 28, 2011 Brian Orelli	Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug.
The Motley Fool June 14, 2010 Brian Orelli	No Approval? No Problem! Investors shrug off Human Genome's news about its hepatitis C drug Zalbin.
The Motley Fool August 5, 2011 Brian Orelli	Still Want to Be the Next Dendreon? The biotech market is punished.
The Motley Fool November 25, 2011 Brian Orelli	7 Black Friday Biotech Bargains Get in at the right time to maximize your returns.
The Motley Fool December 13, 2011 David Williamson	3 Biotechs Making Big Moves on Big News Trial results and FDA panels ruled the health-care sector today.
The Motley Fool November 23, 2011 Brian Orelli	I Was Wrong About Dendreon But maybe not in the long term.
The Motley Fool November 21, 2011 David Williamson	Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977.
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool November 3, 2011 Brian Orelli	Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy.
The Motley Fool January 5, 2012 David Williamson	Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%.
The Motley Fool August 11, 2011 Brian Orelli	Dendreon's a Broken IPO, Again $10 isn't really a magical number.
The Motley Fool October 5, 2010 Brian Orelli	You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure.
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool November 2, 2011 David Williamson	After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool December 16, 2011 Brian Orelli	Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech.
The Motley Fool March 17, 2011 Brian Orelli	Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping.
The Motley Fool December 6, 2010 Brian Orelli	3-Month Delay? No Problem! Investors shrug off HGS' Benlysta delay. The Food and Drug Administration's delaying its decision on whether to approve Human Genome Sciences and GlaxoSmithKline's Benlysta shouldn't come as much of a surprise.
The Motley Fool February 27, 2009 Brian Orelli	Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government.
The Motley Fool November 17, 2010 Brian Orelli	52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval.
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
The Motley Fool July 20, 2009 Brian Orelli	Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.
The Motley Fool August 30, 2007 Brian Lawler	Human Genome Steps Forward Human Genome Sciences investors got good news as the drugmaker took a quicker-than-expected step in its journey to get its lead drug, hepatitis C treatment Albuferon, on the path to FDA approval.
The Motley Fool July 29, 2011 Brian Orelli	Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool August 4, 2011 Brian Orelli	Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse?
The Motley Fool October 26, 2011 Brian Orelli	Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest.
The Motley Fool October 31, 2008 Brian Orelli	World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool July 22, 2010 Rich Smith	This Just In: Upgrades and Downgrades Baird turns bullish on Human Genome Sciences.
The Motley Fool January 30, 2009 Brian Orelli	Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.
The Motley Fool July 5, 2011 Luke Timmerman	Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool June 18, 2009 Daniel Harrison	Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains.
The Motley Fool July 12, 2011 Luke Timmerman	Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool September 27, 2010 Brian Orelli	Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin.
The Motley Fool September 30, 2011 David Williamson	This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
The Motley Fool January 5, 2012 Brian Orelli	Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today.
The Motley Fool December 9, 2008 Brian Orelli	Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences.
The Motley Fool October 26, 2011 Selena Maranjian	Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool January 5, 2012 David Williamson	4 Stocks Beating the Market These stocks were today's biggest gainers.
The Motley Fool January 17, 2007 Brian Lawler	Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool February 9, 2007 Brian Lawler	Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing.
The Motley Fool July 22, 2011 Brian Orelli	It's How You Finish That Matters Human Genome Sciences gained approval of the first drug developed for lupus in half a century, but in its first full quarter on the market Benlysta was uninspiring.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.